CR3022-derived Anti-SARS-CoV-2 RBD mAbs

InvivoGen Kontakt z doradcą
Anti-Spike RBD antibody - Human & mouse isotypes
CR3022-derived Anti-SARS-CoV-2 RBD mAbs

Antibody description

InvivoGen provides a family of Anti-Spike RBD CR3022-derived monoclonal antibodies (mAbs) in multiple human and mouse isotypes. These mAbs feature:

  • the variable region of the CR3022 human mAb that specifically targets the Spike receptor-binding domain (RBD) [1]
  • a constant region that mediates different effector functions depending on the isotype (human IgG1, hIgG1NQ, hIgA1, or hIgM, and mouse IgG2a or mIgG1e3 ) (See Table)

The Anti-Spike RBD clone CR3022 is a SARS-CoV neutralizing antibody that was obtained from the screening of an antibody-phage library and converted to a human IgG1 format [1]. SARS-CoV and SARS-CoV-2 (2019-nCoV) RBD share a highly conserved epitope (86% shared identity) that is recognized by CR3022 [2, 3]. To date, the neutralization potency of CR3022 for SARS-CoV-2 is still unclear [3, 4]. Indeed, CR3022 does not interfere with the ACE2 binding motif [2-4]. 

Applications

  • Detection of the presence of viral particles in culture supernatant or in serum (ELISA)
  • Control of antibody-mediated effector functions  (i.e. absence, increase or decrease in ADCC, ADCP, or CDC) (See Table)

Quality control

  • Isotype confirmed by ELISA
  • Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide

Our CR3022 variants have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.

All the SARS-CoV-2-related antibodies are in stock now and can be shipped out immediately.

Read our reviews discussing SARS-CoV-2

References

  1. Ter Muelen J. et al., 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLos Med. 3(7):e237.
  2. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. DOI: 10.1126/science.abb7269.
  3. Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 9(1):382-385.
  4. Huo J. et al., 2020. Neutralization of SARS-CoV-2 by destruction of the prefusion Spike. bioRxiv. DOI:10.1101/2020.05.05.079202.

Podobne produkty

Anti-β-Gal-hIgG3

Anti-β-Gal-hIgG3

InvivoGen
Więcej
Anti-hCD19-βGal

Anti-hCD19-βGal

InvivoGen
Więcej
Anti-IL-1α

Anti-IL-1α

InvivoGen
Więcej